Advertisement

PharmacoEconomics

, Volume 38, Issue 1, pp 121–122 | Cite as

Comment on: ‘NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence’

  • Livio GarattiniEmail author
  • Nicholas Freemantle
Letter to the Editor

Notes

Compliance with Ethical Standards

Funding

No sources of funding were used to prepare this letter.

Conflict of interest

Nicholas Freemantle and Livio Garattini have no conflicts of interest that are directly relevant to content of this letter.

References

  1. 1.
    Bullement A, Taylor M, McMordie ST, Waters E, Hatswell AJ. NICE, in confidence: an assessment of redaction to obscure confidential information in single technology appraisals by the National Institute for Health and Care Excellence. Pharmacoeconomics. 2019;37(11):1383–90.CrossRefGoogle Scholar
  2. 2.
    van de Vooren K, Curto A, Freemantle N, Garattini L. Market-access agreements for anti-cancer drugs. J R Soc Med. 2015;108(5):166–70.CrossRefGoogle Scholar
  3. 3.
    Curto A, van de Vooren K, Garattini L. Market approval for drugs in the EU: time to change direction? Eur J Health Econ. 2017;18(8):933–6.CrossRefGoogle Scholar
  4. 4.
    Garattini L, Padula A. HTA for pharmaceuticals in Europe: will the mountain deliver a mouse? Eur J Health Econ. 2019.  https://doi.org/10.1007/s10198-019-01103-9. [Epub ahead of print].
  5. 5.
    van de Vooren K, Curto A, Garattini L. Optional copayments on anti-cancer drugs. BMJ. 2013;346:f349.CrossRefGoogle Scholar
  6. 6.
    Garattini L, Padula A. Dutch guidelines for economic evaluation: ‘from good to better’ in theory but further away from pharmaceuticals in practice? J R Soc Med. 2017;110(3):98–103.CrossRefGoogle Scholar
  7. 7.
    Garattini L, Padula A. Pharmaceutical pricing conundrum: time to get rid of it? Eur J Health Econ. 2018;19(8):1035–8.CrossRefGoogle Scholar
  8. 8.
    Mahase E. EU drug approval should include price evaluation, says expert panel. BMJ. 2019;367:l6591.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Centre for Health EconomicsInstitute for Pharmacological Research Mario Negri IRCCSRanicaItaly
  2. 2.Institute of Clinical Trials and MethodologyUniversity College LondonLondonUK

Personalised recommendations